DDInter336 DDInter1725
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into [mesalazine] and [sulfapyridine], 2 compounds that carry out the main pharmacological activity of sulfasalazine. Sulfasalazine was first used in 1940 for rheumatic polyarthritis, and has been firmly established itself as one fo the most useful disease-modifying antirheumatic drug (DMARD). Compared to the first line treatment of RA like methotrexate, sulfasalazine is almost as efficacious as methotrexate although with slightly less tolerability. However, sulfasalazine has less teratogenic side effects and faster onset of action compared to conventional DMARD. Sulfasalazine fell out of favor as the drug of choice for RA due to poorly designed clinical trials in 1950 but regained interest from the clinical community in the late 1970. Although sulfasalazine is only approved by the FDA for ulcerative colitis, research have shown that sulfasalazine is also beneficial for patients with Crohn's disease. Meta-analysis of 19 randomized controlled trials indicated that sulfasalazine is superior to placebo in inducing remission; however, with no supported evidence of mucosal healing, sulfasalazine is not FDA-recommmended for treatment of Crohn's disease.[A255597,A255602,A255607]
Celecoxib {u} (Compound) resembles {v} (Compound) Sulfaphenazole
Sulfaphenazole {u} (Compound) resembles {v} (Compound) Sulfasalazine
Celecoxib {u} (Compound) palliates {v} (Disease) ankylosing spondylitis
ankylosing spondylitis {u} (Disease) is treated by {v} (Compound) Sulfasalazine
Celecoxib {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Sulfasalazine
Celecoxib {u} (Compound) resembles {v} (Compound) Sulfaphenazole
Sulfaphenazole {u} (Compound) resembles {v} (Compound) Sulfadiazine
Sulfadiazine {u} (Compound) resembles {v} (Compound) Sulfasalazine
Celecoxib {u} (Compound) palliates {v} (Disease) ankylosing spondylitis
ankylosing spondylitis {u} (Disease) resembles {v} (Disease) Crohn's disease
Crohn's disease {u} (Disease) is treated by {v} (Compound) Sulfasalazine
Celecoxib {u} (Compound) resembles {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vismodegib
Vismodegib {u} (Compound) resembles {v} (Compound) Sulfasalazine
Celecoxib {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Olsalazine
Olsalazine {u} (Compound) resembles {v} (Compound) Sulfasalazine
Celecoxib {u} (Compound) palliates {v} (Disease) ankylosing spondylitis
ankylosing spondylitis {u} (Disease) resembles {v} (Disease) ulcerative colitis
ulcerative colitis {u} (Disease) is treated by {v} (Compound) Sulfasalazine
Celecoxib {u} (Compound) palliates {v} (Disease) rheumatoid arthritis
rheumatoid arthritis {u} (Disease) is associated with {v} (Gene) and {u} (Disease) upregulates {v} (Gene) ALOX5
ALOX5 {u} (Gene) is bound by {v} (Compound) Sulfasalazine
Celecoxib {u} (Compound) resembles {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is bound by {v} (Compound) Sulfasalazine
Celecoxib (Compound) resembles Sulfaphenazole (Compound) and Sulfaphenazole (Compound) resembles Sulfasalazine (Compound)
Celecoxib (Compound) palliates ankylosing spondylitis (Disease) and ankylosing spondylitis (Disease) is treated by Sulfasalazine (Compound)
Celecoxib (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Sulfasalazine (Compound) and PTGS2 (Gene) is upregulated by Sulfasalazine (Compound)
Celecoxib (Compound) resembles Sulfaphenazole (Compound) and Sulfaphenazole (Compound) resembles Sulfadiazine (Compound) and Sulfadiazine (Compound) resembles Sulfasalazine (Compound)
Celecoxib (Compound) palliates ankylosing spondylitis (Disease) and ankylosing spondylitis (Disease) resembles Crohn's disease (Disease) and Crohn's disease (Disease) is treated by Sulfasalazine (Compound)
Celecoxib (Compound) resembles Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vismodegib (Compound) and Vismodegib (Compound) resembles Sulfasalazine (Compound)
Celecoxib (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Olsalazine (Compound) and Olsalazine (Compound) resembles Sulfasalazine (Compound)
Celecoxib (Compound) palliates ankylosing spondylitis (Disease) and ankylosing spondylitis (Disease) resembles ulcerative colitis (Disease) and ulcerative colitis (Disease) is treated by Sulfasalazine (Compound)
Celecoxib (Compound) palliates rheumatoid arthritis (Disease) and rheumatoid arthritis (Disease) is associated with ALOX5 (Gene) and rheumatoid arthritis (Disease) upregulates ALOX5 (Gene) and ALOX5 (Gene) is bound by Sulfasalazine (Compound)
Celecoxib (Compound) resembles Etoricoxib (Compound) and Etoricoxib (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is bound by Sulfasalazine (Compound)